Collaborations and Other Arrangements (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Apr. 30, 2022	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue		$ 7,810.0	$ 6,805.6
Petra | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired IPR&D and development milestones	$ 335.0
China
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue		406.5	362.2
Jardiance
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue		419.4	312.0
Trajenta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue		92.0	94.6
Basaglar
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue		191.5	246.6
Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue		255.6	193.8
COVID-19 Antibodies
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue		1,469.8	810.1
Tyvyt®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue		85.5	$ 109.7
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Jardiance
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements		131.1		$ 136.1
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Trajenta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements		82.0		88.5
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Basaglar
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements		$ (144.6)		(149.3)
Royalty Agreement Terms | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, percentage (up to)		20.00%
Milestone Payments, Capitalized as Intangible Assets | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements		$ 260.0		260.0
Milestone Payments, Capitalized as Intangible Assets | Tyvyt®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements				$ 40.0
Milestone Payments, Development and Regulatory | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements		70.0
Milestone Payments, Development and Regulatory | Lebrikizumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements		85.0
Milestone Payments, Sales-based | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements		100.0
Milestone Payments, Sales-based | Lebrikizumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements		1,250.0
Innovent Biologics, Inc. | Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt® | Non-CHINA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements		825.0
Innovent Biologics, Inc. | Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt® | China
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements		195.0
Roche | Milestone Payments, Development and Regulatory | Lebrikizumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements		180.0
Roche | Milestone Payments, Sales-based | Lebrikizumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements		$ 1,030.0